Lords Mark Microbiotech Pvt. Ltd., a subsidiary of Lords Mark Industries, has secured accreditation from NABL, the National Accreditation Board for Testing and Calibration Laboratories, a certification that places the company among India’s most credible and quality‑assured diagnostic providers.
This accreditation reflects adherence to rigorous standards of lab testing, reliability in diagnostics and reporting precision — offering assurance of technical competence and increased patient trust.
Leveraging this milestone, Lords Mark Microbiotech has unveiled an ambitious national expansion plan. Over the next two years, the company intends to establish 200 laboratories and 2,000 collection centres across India — a major scaling-up from its current network, which comprises 12 advanced laboratories and 68 collection centres.
This expansion positions the company to emerge among the top five organised pathology and diagnostics providers in the country.
Central to its differentiated approach is a proprietary health‑evaluation tool named the “Organ Health Score.” This model is designed to offer personalised health assessments, enabling early detection and preventive care rather than relying solely on episodic diagnosis. Through this, Lords Mark Microbiotech aims to shift the paradigm toward proactive, continuous health management for individuals.
This push reflects a broader trend in India’s healthcare sector toward accessible, quality diagnostics and preventive care. By combining accredited laboratories, extensive reach through collection centres, and advanced diagnostics — including genomic screening — Lords Mark seeks to deliver integrated healthcare services across demographic and geographic boundaries.
As the company scales operations and rolls out its preventive health infrastructure, the accreditation from NABL serves as a critical quality benchmark. It lends legitimacy to the company’s commitment to accuracy, reliability and high‑standard diagnostic services.
With this initiative, Lords Mark Microbiotech appears poised to play a significant role in transforming India’s diagnostic and preventive‑healthcare landscape — enabling individuals to access advanced lab testing and personalised health insights that could lead to earlier interventions and better health outcomes at scale.
